Denali Therapeutics (DNLI) Share-based Compensation (2017 - 2026)

Denali Therapeutics (DNLI) has 10 years of Share-based Compensation data on file, last reported at $23.1 million in Q1 2026.

• Quarterly Share-based Compensation fell 8.24% year-over-year to $23.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $97.6 million (down 2.63% YoY) and the FY2025 annual result came in at $99.6 million, down 3.15% from the prior year.
• Share-based Compensation slipped to $23.1 million in Q1 2026 per DNLI's latest filing, from $24.0 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $28.1 million in Q1 2023 and bottomed at $23.1 million in Q1 2026.
• The 5-year median for Share-based Compensation is $25.2 million (2025), against an average of $25.5 million.
• The widest annual swing landed in 2022, when Share-based Compensation gained 24.33%; it then retreated 9.63% in 2025.
• Tracing DNLI's Share-based Compensation over 5 years: stood at $25.2 million in 2022, then rose by 3.18% to $26.0 million in 2023, then retreated by 3.5% to $25.1 million in 2024, then retreated by 4.49% to $24.0 million in 2025, then decreased by 3.61% to $23.1 million in 2026.
• Per Business Quant, the three latest DNLI Share-based Compensation figures stand at $23.1 million (Q1 2026), $24.0 million (Q4 2025), and $25.1 million (Q3 2025).

Peer Comparison